Kornimate/medical-research-clean huggingface dataset:
pharmacokinetics of citalopram in patients with short bowel syndrome

Conditions: Short Bowel Syndrome

Summary: this study will look at how the body interacts with citalopram in adult participants with short bowel syndrome. while information on depression in patients with short bowel syndrome is sparse, the investigators' experience is that these patients have a high incidence of depression and should benefit from a drug intervention.

this prospective study will determine the pharmacokinetic parameters of citalopram in 12 adult patients with short bowel syndrome. while data on the prevalence of depression in patients with short bowel syndrome is sparse, the investigators' experience is that these patients have a high incidence of depression and should benefit from a psychopharmacological intervention.

Eligibility criteria:
inclusion criteria: * subjects must be between the ages 19-65 years. * subjects must have less than 200cm of functional small intestine. * subjects must be at least one month post bowel resection. exclusion criteria: * subjects less than 19 years or more than 65 years of age. * pregnant or breastfeeding women. * known hypersensitivity to citalopram or other ssris. * diagnosis of depression using mini (mini international neuropsychiatric interview). * ongoing antidepressant therapy. * evidence of cirrhosis (child-pugh stages b or c) or evidence of significant liver impairment defined as liver enzymes elevations greater that 2.5 times the upper limit of normal. * suicidal ideation. * bipolar disorder. * mania. * known history of seizures. * evidence of hyponatremia.

Keywords: citalopram pharmacokinetics short bowel syndrome
comparison of different types of surgery in treating patients with early-stage non-small cell lung cancer

Conditions: Stage IA Non-small Cell Lung Cancer; Adenocarcinoma of the Lung; Squamous Cell Lung Cancer

Summary: the purpose of this study is to compare early-stage peripheral non-small cell lung cancer lobectomy and sub-lobectomy surgery to evaluate if sub-lobectomy is as feasible and effective for the treatment of early-stage (diameter ≤2cm) peripheral non-small cell lung cancer as lobectomy.

objectives:to establish a database of patients with early lung cancer surgery,and evaluate if sub-lobectomy surgery is as feasible and effective as lobectomy surgery in patients with early-stage peripheral non-small cell lung cancer,by assessing the retainability of lung function.and improvement of quality of life in those patients. outline:this is a prospective, matched, controlled, open, multi-center clinical study. select the early-stage peripheral nsclc 630 patients (diameter≤2cm), according to age and lesion type (ggo component ratio) two matching factor of 1: 2 assigned to sub-lobectomy group and lobectomy group.patients are followed up every 3 months for the first year and then every 6 months for the other 4 years.

Eligibility criteria:
inclusion criteria: 1. clinically diagnosed with stage i peripheral non-small cell lung cancer suitable for lobectomy. 2. t≤2cm，n0，m0. 3. aged 60 to 80 years old. 4. ecog≤2. 5. according to the ministry of health, "with primary lung cancer diagnostic and treatment practices" (2011 edition) completed preoperative clinical staging examination. 6. voluntary participation, signed informed consent. exclusion criteria: 1. pathologic stage is n1, n2, or m1a. 2. received postoperative adjuvant therapy (chemotherapy or targeted therapy). 3. radiotherapy or chemotherapy before surgery. 4. small cell lung cancer 5. benign lesions 6. patient unwilling to cooperate with surgery or observation.

Keywords: carcinoma, non-small-cell lung lung neoplasms carcinoma, bronchogenic bronchial neoplasms
a probiotic blend reduces gastrointestinal symptoms and positively impacts microbiota modulation in a randomized study

Conditions: Microbiota; Constipation; Candida

Summary: this randomized, placebo-controlled, double-blind study will determine the effect of daily supplementation with a probiotic blend in 60 apparently healthy men and women recruited at a single investigational center in northeast ohio (i.e., the center for applied health sciences). subjects will attend three study visits. during visit 1, subjects will be screened for participation \[i.e., medical history, routine blood work, background baseline diet\]. during visits 2 and 3 subjects will complete questionnaires that assess their gastrointestinal health (e.g., abdominal discomfort/bloating, constipation, regularity, stool consistency). visits 2 and 3 will correspond to before (week 0) and after six weeks of supplementation, respectively, with the probiotic dietary supplement or placebo.


Eligibility criteria:
inclusion criteria: * all participants were required to be between 30-60yr * score ≥12 on the gsrs * have a body mass ≥120 pounds (54.5kg) * body mass index (bmi) between 20.0-34.99kg/m2 * normotensive (\<140/\<90mmhg) * normal resting heart rate (\<90bpm) exclusion criteria: * female participants who were pregnant or nursing * history of unstable or new-onset cardiovascular or cardiorespiratory disease; * stroke, diabetes, or other endocrine disorder; * use of any nutritional supplement known to alter the gut microbiota/microflora; * use of probiotic supplements or prebiotic supplements in the previous 4 weeks and for the duration of the study; * use of any antibiotics, antifungals, antivirals, or antiparasitic within 8 weeks of the start of the study or throughout the study; * any changes in diet within 4 weeks of study start date or throughout study duration; * if the participant was unwilling to abstain from gut altering supplements for the study; * malignancy in the previous 5yr except for non-melanoma skin cancer (basal cell cancer or squamous cell cancer of the skin); * prior gastrointestinal bypass surgery (i.e., lapband); * any known gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism \[e.g. short bowel syndrome, diarrheal illnesses, history of colon resection, gastroparesis, inborn-errors-of-metabolism (such as pku)\]; * any chronic inflammatory condition/disease (e.g. rheumatoid arthritis, crohn's disease, ulcerative colitis, lupus, hiv/aids, etc.); * known sensitivity to any ingredient in the test formulations as listed in the certificates of analysis. * currently participating in another research study with an investigational product or had participated in another research study in the past 30 days * any other diseases/conditions that, in the opinion of the medical staff, could confound the primary endpoints or place the subject at increased risk of harm if they were to participate.
pd-1 antibody combined with chemoradiotherapy in recurrent nasopharyngeal carcinoma patients

Conditions: Recurrent Nasopharyngeal Carcinoma

Summary: this is a multicenter, randomized controlled, phase iii clinical trial. the purpose of this study is to evaluate the efficacy and adverse effect of pd-1 antibody with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.


Eligibility criteria:
inclusion criteria: * diagnosed as local recurrence ± regional recurrence after ≥1 year of radical treatment; * not suitable for surgery; * newly histologic diagnosis of npc (who ii/iii); * clinical stage rii-iva (ajcc/uicc 8th); * ecog 0-1 point; * no treatment to rnpc, such as radiotherapy, chemotherapy, immunotherapy or biotherapy; * no contraindications to immunotherapy or radiotherapy; * adequate marrow function: wbc count ≥ 3×10e9/l, ne count ≥ 1.5×10e9/l, hgb ≥ 90g/l, plt count ≥ 100×10e9/l; * adequate liver function: alt/ast ≤ 2.5×uln, tbil ≤ 2.0×uln; * adequate renal function: bun/cre ≤ 1.5×uln or endogenous creatinine clearance ≥ 60ml/min (cockcroft-gault formula); * take effective contraceptions during and two months after treatment; * patients must be informed of the investigational nature of this study and give written informed consent. exclusion criteria: * treated with anti-tumor chinese medicine treatment; * have recurrence with local necrosis; * have ≥g3 late toxicities, except for skin, subcutaneous tissue or mucosa; * unexplained fever \> 38.5 ℃, except for tumor fever; * treated with ≥ 5 days antibiotics one month before enrollment; * have active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy); have a known history of human immunodeficiency virus (hiv), active hepatitis b (hbv-dna ≥10e4copiers/ml) or hepatitis c virus (hcv) antibody positive; have previously treated with pd-1 antibody or other immunotherapy for pd-1/pd-l1 pathway; * have new york heart association (nyha) class 3 or 4, unstable angina, myocardial -infarction within 1 year, or clinically meaningful arrhythmia that requires treatment; * have known allergy to large molecule protein products or any compound of study therapy; * pregnant or breastfeeding; * prior malignancy except adequately treated non-melanoma skin cancer, in situ cervical cancer, and papillary thyroid carcinoma; * have received a live vaccine within 30 days of planned start of study therapy has psychiatric drug or substance abuse disorders that would interfere with cooperation with the requirements of the trial; * any other condition, including mental illness or domestic/social factors, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results.

Keywords: pd-1 antibody intensity-modulated radiation therapy efficacy adverse effect chemotherapy
regional citrate anticoagulation for rrt during v-v ecmo

Conditions: ARDS, Human; Acute Kidney Injury

Summary: anticoagulation is an essential component of all extracorporeal therapies. currently locoregional citrate anticoagulation is the recommended technique for continuous renal replacement therapy (crrt). however, low clearance of citrate restricts its use to blood flow up to 150 ml/min, preventing its use in ecmo. renal replacement therapy (rrt) is commonly provided to ecmo patients with aki. in presence of systemic heparinization for ecmo, additional anticoagulation for the crrt circuit (i.e. rca) is usually not employed. nevertheless, thrombosis occurs more frequently in the crrt circuit than the oxygenator because of the slower blood flow. the aim of this prospective, cross-over study is to assess, in patients undergoing crrt during veno-venous ecmo (vv-ecmo), the efficacy and safety of adding regional citrate anticoagulation (rca) for crrt circuit anticoagulation.


Eligibility criteria:
inclusion criteria: * patients admitted in icu * v-v ecmo support for acute respiratory failure * crrt therapy for acute kidney injury exclusion criteria: * pregnancy * pre-existing coagulation disorders * contraindication to heparin or citrate anticoagulation * moribund patients

Keywords: extracorporeal membrane oxygenation acute kidney injury ards renal replacement therapy
a multi-centre study comparing the effects of azd2927 and placebo on the electrical activity in the heart in patients

Conditions: Arrhythmia

Summary: medical products agency

* a multi-centre, double-blind, randomised, placebo-controlled phase ii study to assess the effects on atrial and ventricular refractoriness of an intravenous infusion of azd2927 in patients undergoing an invasive electrophysiological procedure. * the study has an adaptive design. in the 1st dose group the planned number of randomised patients is 24. the tentative number of randomised patients in the optional 2nd dose group is 12, 24 or 36 and thus a total maximum of 60 patients will be randomised in the study.

Eligibility criteria:
inclusion criteria: * male or postmenopausal female, aged 20 to 80 years inclusive, * clinical indication for catheter ablation of atrial flutter, * history of paroxysmal atrial flutter, with or without paroxysmal af. single episodes of persistent atrial flutter or af requiring cardioversion do not exclude the patient from the study, * sinus rhythm at randomisation, * adequate anticoagulation or antithrombotic treatment according to esc guidelines 2010 or national guideline, exclusion criteria: * cardioversion within 14 days before randomisation, * history of stroke or transient ischaemic attack (tia). history of significant head trauma, epilepsy or other disorders increasing the risk for seizures, * qtcf \>450 ms or \<350 ms measured in sinus rhythm at randomisation, * history and/or signs of clinically significant sinus node dysfunction. sinus bradycardia (50 beats per minute or less) at randomisation, * personal or family history of torsades de pointes (tdp), any other polymorphic ventricular tachycardia, long qt syndrome, short qt syndrome, brugada syndrome, or personal history of sustained (\>30 s) monomorphic ventricular tachycardia.

Keywords: atrial refractoriness cardiac electrophysiology ikach
effect of om-85 bv on wheezing related morbidity in children with recurrent wheezing

Conditions: Asthma

Summary: the purpose of this study is to determine whether om-85 bv (broncho-vaxom)has any effect on respiratory infections, infection related wheezing attacks, beta-2 agonist use, duration of attacks and effect on serum cytokine levels.

context: respiratory infections are the major cause of wheezing attacks in children with recurrent wheezing or asthma in preschool age. om-85 bv is an bacteria lysate which has been proven to prevent respiratory infections about 40 percent in children. objective: to determine if using om-85 bv diminish the number and duration of the respiratory infections and respiratory infection related wheezing attacks,beta-2 agonist and steroid use, and number and duration of hospitalizations in children with recurrent wheezing and asthma. and also to determine if om-85 bv has any effect on serum cytokine levels after 6 months. study design/setting/participants: a double-blind, randomized, controlled trial of om-85 bv versus placebo for children 6 months to 6 years of age who have respiratory tract infection related recurrent wheezing attacks. intervention: participants will receive either active broncho-vaxom or placebo for 3 months. study measures: they follow up for 1 year for number and duration of wheezing attacks, number, type and duration of respiratory infections, number and duration of beta-2 agonist use, number and duration of steroid use and number and duration of hospitalizations. serum cytokine levels will measure to determine if broncho-vaxom has any effect on serum cytokine levels (at the beginning of the trial and sixth months of the trial).

Eligibility criteria:
inclusion criteria: * children with recurrent wheezing who had at least 3 wheezing attacks in the last 6 months * children with asthma who had at least 3 wheezing attacks in the last 6 months exclusion criteria: * chronic lung disease * immun deficiency * malabsorption * anatomic abnormalities of the respiratory tract * gastroesophageal reflux disease

Keywords: wheezing asthma childhood om-85 bv broncho-vaxom
brachio basilic arterio venous fistula one stage vs two stage

Conditions: Arterio-venous Fistula

Summary: the aim of this work was to compare primary failure rates and the primary functional patency of one-stage vs two stage brachiobasilic fistulas to compare the two surgical techniques .

in the last two decades, there have been concerted efforts by the national kidney foundation dialysis outcomes quality initiative (nkf-doqi), and the fistula first breakthrough initiative to decrease the use of prosthetic grafts and increase autogenous (native) arteriovenous fistula(avf) creation for hemodialysis access. when considering vascular access for hemodialysis on the basis of patency, resistance to infection,and associated complications, native avf should be selected as the first choice whenever possible. if the cephalic vein in the upper arm is unusable for avf construction, the basilic vein can be superficialized and anastomosed to the brachial artery at the elbow to form a brachiobasilic arteriovenous fistula (bb)avf . if a bb avf is to be constructed,duplex ultrasound should be used to check the path and size of the basilic vein. it is also important to determine if an adequate length can be mobilized . the bb fistulae can be formed in one stage or two stages. to date, limited and conflicting data exist regarding primary failure and the patency rates of one-stage and two-stage procedures. each procedure has advantages and disadvantages both one-stage and two-stage procedures have their advantages and disadvantages. which procedure results in improved outcomes remains unclear. however, the basic principle is to superficialize the basilic vein and make it amenable to needle puncture.

Eligibility criteria:
inclusion criteria: * all patients with end-stage renal disease who had their bbavfs created either by the one-stage or two- stage technique. * patients with brachial artery diameter more than 3 . mm by duplex ultrasound (dus). * patients with triphasic brachial artery by dus. * patients with basilic vein diameter more than 3 mm by dus. * patients who were able to give informed consent. * requirements for intervention agreement between the patient and the surgeon. * availability of patients for all follow-up visits. exclusion criteria: * patients who already had a suitable cephalic vein for arteriovenous fistula creation. * patients whose brachial artery diameter was less than 3 mm by dus. * patients with brachial artery disease proved by dus. * patients whose basilic vein diameter was less than mm by dus. * patients with ischemic cardiomyopathy. * patients with central venous stenosis or occlusion evidenced by duplex scanning. * patients with flexion deformity or skin lesions at the site of the fistula or over the course of the vein.
review of charts from amish/mennonite variant pa patients

Conditions: Propionic Acidemia

Summary: the natural history of patients with pa-amv has not been systematically studied before and there is no published data in the literature about this condition since 1980. there is no evidence-based approach to care of these patients, particularly the younger patients who may no come to medical attention until significant cardiac problems develop. through systematic review of existing medical records on essentially all known patient with this condition, investigators plan to develop an evidence-based management plan for preventive care of these patients.

the study is designed to provide a comprehensive description of the clinical and biochemical features of propionic academia, amish/mennonite variant (pa-amv). from these data, the investigators hope to identify biomarkers for assessment of clinical course and efficacy of ongoing management. the investigators plan to identify essentially all known patients who have the amish/mennonite variant of propionic academia (pa-amv) through collaboration with clinicians who proved care to this extended community. signed consents include permission to access life-long medical records to allow investigators to define the natural history of this biochemical variant condition. this will include a description the clinical and biochemical features and natural history of patients with propionic acidemia in the amish/mennonite population. in particular, there is interest in the cardiac complications of this variant, so investigators will analyze ekg, echo and cardiac mri findings in above patients. these data will be used to identify biomarkers for clinical assessment and ongoing management. there has been no published data on patients with pa-amv since 1980. accumulated clinical experience with pa amish/mennonite variant patients suggests that these patients tend to have less severe clinical features compared to classic pa. severe neonatal metabolic decompensation and ketoacidosis are not present in amish/mennonite patients we have followed. describing the natural history and clinical course is essential in this group of patients to further guide their management. there is currently no evidence-based approach to care of these patients, but rather individual medical centers manage patients symptomatically and differently. a uniform, data-driven approach to patient management is needed.

Eligibility criteria:
inclusion criteria: * patients homozygous for the pccb c.606a\>g mutation exclusion criteria: * patients who are not homozygous for the pccb c.1606a\>g mutation

Keywords: amish/mennonite variant
subcutaneous treprostinil as a bridge to lung transplantation in severe pulmonary hypertension: a single-arm retrospective study

Conditions: Pulmonary Hypertension; Pulmonary Arterial Hypertension; Chronic Lung Disease-Associated Pulmonary Hypertension; Lung Transplantation; Heart Failure

Summary: this single-arm, retrospective study aims to evaluate the safety and efficacy of subcutaneous treprostinil as a bridge therapy for lung transplantation in patients with severe pulmonary hypertension (ph). a total of 46 patients with either pulmonary arterial hypertension (pah) or chronic lung disease-associated ph (cld-ph) were included, all of whom were referred for lung transplantation between january 1, 2015, and september 1, 2024. the study examines changes in clinical, functional, and hemodynamic parameters following 3-6 months of treprostinil therapy.

this study evaluates the use of subcutaneous treprostinil as a bridge therapy for lung transplantation in patients with severe pulmonary hypertension (ph), including both pulmonary arterial hypertension (pah) and chronic lung disease-associated ph (cld-ph). this retrospective, single-center study included 46 patients treated between january 1, 2015, and september 1, 2024. all patients experienced significant clinical and hemodynamic impairment at the time of treprostinil initiation. the primary aim was to assess improvements in nyha functional class and 6-minute walk distance (6-mwd) following 3-6 months of therapy. secondary outcomes included nt-probnp levels, echocardiographic parameters, and post-transplantation survival rates. the study also analyzed the incidence of primary graft dysfunction (pgd) and the continued use of treprostinil post-transplantation.

Eligibility criteria:
inclusion criteria: * patients diagnosed with severe pulmonary hypertension (pah or cld-ph) requiring lung transplantation * age 18 years or older * able to provide informed consent exclusion criteria: * patients with ph caused by left heart disease * patients unable to undergo lung transplantation due to medical conditions * patients with a history of severe drug allergies

Keywords: subcutaneous treprostinil nyha functional class 6-minute walk distance primary graft dysfunction (pgd) retrospective study single-arm study